Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 2;6(8):e757.
doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug.

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

Claire Harrison  1 , Florian H Heidel  2 , Alessandro M Vannucchi  3 , Jean-Jacques Kiladjian  4 , Amjad Hayat  5 , Francesco Passamonti  6 , Eibhlin Conneally  7 , Thomas Kindler  8 , Bruno Martino  9 , Daniel B Lipka  10 , Tommaso Stefanelli  11 , Pantelia Roussou  11 , Davide Germano  11 , Jacqueline Ewan  12 , Vincent Ribrag  13
Affiliations

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

Claire Harrison et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Best percentage change at any time. (A) Best percentage change in spleen volume for all patients in expansion Phase. Two patients who had no available post-baseline spleen volume assessments are not summarized. Reference line indicates −35% change from baseline. (B) Best percentage change in spleen length (cm) from baseline by group of treatment duration (full analysis set). One patient who had no available post-baseline spleen length assessments was not summarized. Reference line indicates −50% change from baseline. The values on each bar indicates baseline spleen length (cm). DEP = dose-expansion phase.
See this image and copyright information in PMC

References

    1. Keohane C, Radia DH, Harrison CN. Treatment and management of myelofibrosis in the era of JAK inhibitors. Biologics. 2013;7:189–198.. - PMC - PubMed
    1. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233–245.. - PubMed
    1. Cervantes F, Dupriez B, Pereira A, et al. . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.. - PubMed
    1. Mascarenhas J, Lu M, Li T, et al. . A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013;161:68–75.. - PubMed
    1. Evrot E, Ebel N, Romanet V, et al. . JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res. 2013;19:6230–6241.. - PubMed